Schiff Nutrition Acquires Airborne, Inc., a Leading Brand in Immunity
Support

SALT LAKE CITY--(BUSINESS WIRE)--Schiff Nutrition International, Inc., (NYSE: WNI), acquired Airborne,
Inc., a leading provider of immune support products on March 30, 2012
for $150 million in cash, subject to certain adjustments.

“Schiff is focused on building premium brands and leading innovation,”
stated Tarang Amin, president and chief executive officer. “We are
excited about the Airborne acquisition, which fits well with our
strategy and establishes Schiff as a leader in the immune support
segment. Airborne is a strong brand and will make an excellent addition
to Schiff’s portfolio, and we plan to leverage our science, innovation,
marketing and sales capabilities to further its growth.”

Airborne develops and sells innovative dietary supplements throughout
the United States and Canada, as well as online. Its Airborne health
formula is designed to support customers’ immune systems through its
unique combination of vitamins, nutrients and proprietary blend of
herbal extracts. Its immune support products include iconic effervescent
tablets, new chewable tablets and on-the-go packets, all in a variety of
flavors.Airborne can be visited online at www.airbornehealth.com.

Marti Morfitt, Airborne, Inc.’s chief executive officer, stated: “I am
very proud of the work the Airborne team has done over the past three
years to re-establish the growth of the brand and to develop a strong
pipeline of new products and marketing programs designed to support the
future growth of the business. We are happy to see our business move to
the team at Schiff – they bring great talent and resources to the
business and share our passion for building a leading immune support
brand.”

“Schiff intends to couple Airborne’s leading brand and product portfolio
with our strong capabilities in science and innovation,” continued Amin.
“For example, there has been promising scientific research into the
potential relationship between BC30, the proprietary
probiotics technology we acquired rights to last year, and supporting
the immune system. We are currently conducting a study with Dr. Glenn R.
Gibson at The University of Reading in the UK on the effects of BC30
on the immune function of healthy elderly persons. This is but one of
the many potential opportunities to bring science and innovation to
Airborne.”

Terms of Deal and Financial Impact

Under the terms of the purchase agreement, Schiff acquired 100% of
Airborne’s stock from GF Capital Private Equity Fund, LP for $150
million, subject to certain adjustments. Schiff funded the all-cash
transaction through a combination of a new debt facility and cash on its
balance sheet.

Airborne, Inc. generated net revenue of approximately $70 million for
the twelve months ended February 29, 2012. Preliminarily, the company
expects to recognize transaction related costs of approximately $4.5
million in fiscal 2012, of which $0.9 million was recognized during the
third fiscal quarter.

The transaction is expected to become accretive during the first half of
fiscal year 2014. The company is in the process of finalizing its
overall cost of capital, completing its valuation of the acquired
business, including allocation of purchase price to primarily intangible
assets, and determining the expected timing of certain synergies.
Management expects to further address the overall impact of the
acquisition on its financial results and future outlook when it
announces its fourth quarter and fiscal 2012 financial results.

Houlihan Lokey acted as financial advisor to Schiff in connection with
the transaction.

Conference Call Information

Schiff will hold a conference call today, April 2nd, at 1:00
p.m. ET. The event will be webcast at the company’s website at www.schiffnutrition.com.
The webcast replay will be available for 90 days. If you do not have
Internet access, the dial-in number will be 1-866-700-0161 for domestic
callers and 1-617-213-8832 for international callers. The participant
pass code is 86364520. A replay of the call will be available by dialing
1-888-286-8010 for domestic callers and 1-617-801-6888 for international
callers, and entering pass code 35086433. The telephone replay will be
available through April 9, 2012.

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 that are based on management’s
beliefs and assumptions, current expectations, estimates, and
projections. These statements are subject to known and unknown risks and
uncertainties, certain of which are beyond the company’s ability to
control or predict, and therefore, actual results may differ materially.
For example, statements concerning future benefits, opportunities and
the financial impact of the acquisition of Airborne are forward-looking
statements. Any forward-looking statements are made pursuant to the
Private Securities Litigation Reform Act of 1995 and, as such, speak
only as of the date hereof. Schiff disclaims any obligation to update
any forward-looking statements whether as a result of new information,
future events or otherwise. You are cautioned not to place undue
reliance on these forward-looking statements.

Important factors that may cause actual results of Schiff to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: the inability to
successfully integrate Airborne into Schiff’s operations or to achieve
the anticipated synergies, benefits or other opportunities of the
Airborne acquisition, the inability to perform obligations under, or to
operate within the constraints of, the new debt facility, dependence on
sales of Schiff Move Free product and the joint care category,
dependence on sales of Schiff MegaRed product, dependence on individual
customers, adverse publicity or consumer perception regarding our
nutritional supplements and/or their ingredients, similar products
distributed by other companies or the nutritional supplement industry
generally, the impact of competitive products and pricing pressure
(including expansion of private label products), the inability to
successfully bid on new and existing private label business, the impact
of raw material pricing, availability and quality (particularly relating
to joint care products and ingredients from third-party suppliers
outside the United States, including China), claims that our products
infringe the intellectual property rights of others, the inability to
enforce or protect our intellectual property rights and proprietary
techniques against infringement, the inability to successfully launch
and maintain sales (especially in the joint care and omega-3 categories)
outside of the United States while maintaining the integrity of the
products sold and complying with local regulations, the inability to
appropriately respond to changing consumer preferences and demand for
new products, the inability to gain or maintain market distribution for
new products or product enhancements, including products in the
probiotic space, litigation and government or administrative regulatory
action in the United States and internationally, including FDA
enforcement and product liability claims, the inability or increased
cost to obtain sufficient levels of product liability and general
insurance, the inability to comply with existing or new regulations,
both in the United States and abroad, and adverse actions regarding
product formulation, claims or advertising, product recalls or a
significant amount of product returns, dependence on a single
manufacturing facility and potential disruptions of our manufacturing
operations, the inability to find strategic transaction opportunities or
the inability to successfully consummate or integrate a strategic
transaction (including the inability to successfully integrate the
business recently acquired from Airborne), the inability to maintain or
attract key personnel, interruptions to our information technology
systems, control by our principal stockholders, and other factors
indicated from time to time in the company’s SEC reports, copies of
which are available upon request from the company’s investor relations
department or may be obtained at the SEC's web site (www.sec.gov).
These risks and uncertainties should be carefully considered before
making an investment decision with respect to shares of our common stock.